Microbes, Clinical trials, Drug Discovery, and Vaccine Development: The Current Perspectives

Because of the frequent emergence of novel microbial species and the re-emergence of genetic variants of hitherto known microbes, the global healthcare system, and human health has been thrown into jeopardy. Also, certain microbes that possess the ability to develop multi-drug resistance (MDR) have...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Venkataramana Kandi, Tarun Kumar Suvvari, Sabitha Vadakedath, Vikram Godishala
Formato:	article
Lenguaje:	EN ID
Publicado:	Institute for Researches and Community Services Universitas Muhammadiyah Palangkaraya 2021
Materias:	emergence re-emergence novel microbes human health multi-drug resistance drug discovery Pharmacy and materia medica RS1-441
Acceso en línea:	https://doaj.org/article/3bf383f07f1444fe90c3cc054d9d84e5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3bf383f07f1444fe90c3cc054d9d84e5
record_format	dspace
spelling	oai:doaj.org-article:3bf383f07f1444fe90c3cc054d9d84e52021-12-01T04:44:02ZMicrobes, Clinical trials, Drug Discovery, and Vaccine Development: The Current Perspectives10.33084/bjop.v4i4.25712621-4814https://doaj.org/article/3bf383f07f1444fe90c3cc054d9d84e52021-11-01T00:00:00Zhttp://journal.umpalangkaraya.ac.id/index.php/bjop/article/view/2571https://doaj.org/toc/2621-4814Because of the frequent emergence of novel microbial species and the re-emergence of genetic variants of hitherto known microbes, the global healthcare system, and human health has been thrown into jeopardy. Also, certain microbes that possess the ability to develop multi-drug resistance (MDR) have limited the treatment options in cases of serious infections, and increased hospital and treatment costs, and associated morbidity and mortality. The recent discovery of the novel Coronavirus (n-CoV), the Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2) that is causing the CoV Disease-19 (COVID-19) has resulted in severe morbidity and mortality throughout the world affecting normal human lives. The major concern with the current pandemic is the non-availability of specific drugs and an incomplete understanding of the pathobiology of the virus. It is therefore important for pharmaceutical establishments to envisage the discovery of therapeutic interventions and potential vaccines against the novel and MDR microbes. Therefore, this review is attempted to update and explore the current perspectives in microbes, clinical research, drug discovery, and vaccine development to effectively combat the emerging novel and re-emerging genetic variants of microbes. Venkataramana KandiTarun Kumar SuvvariSabitha VadakedathVikram GodishalaInstitute for Researches and Community Services Universitas Muhammadiyah Palangkaraya articleemergencere-emergencenovel microbeshuman healthmulti-drug resistancedrug discoveryPharmacy and materia medicaRS1-441ENIDBorneo Journal of Pharmacy, Vol 4, Iss 4 (2021)
institution	DOAJ
collection	DOAJ
language	EN ID
topic	emergence re-emergence novel microbes human health multi-drug resistance drug discovery Pharmacy and materia medica RS1-441
spellingShingle	emergence re-emergence novel microbes human health multi-drug resistance drug discovery Pharmacy and materia medica RS1-441 Venkataramana Kandi Tarun Kumar Suvvari Sabitha Vadakedath Vikram Godishala Microbes, Clinical trials, Drug Discovery, and Vaccine Development: The Current Perspectives
description	Because of the frequent emergence of novel microbial species and the re-emergence of genetic variants of hitherto known microbes, the global healthcare system, and human health has been thrown into jeopardy. Also, certain microbes that possess the ability to develop multi-drug resistance (MDR) have limited the treatment options in cases of serious infections, and increased hospital and treatment costs, and associated morbidity and mortality. The recent discovery of the novel Coronavirus (n-CoV), the Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2) that is causing the CoV Disease-19 (COVID-19) has resulted in severe morbidity and mortality throughout the world affecting normal human lives. The major concern with the current pandemic is the non-availability of specific drugs and an incomplete understanding of the pathobiology of the virus. It is therefore important for pharmaceutical establishments to envisage the discovery of therapeutic interventions and potential vaccines against the novel and MDR microbes. Therefore, this review is attempted to update and explore the current perspectives in microbes, clinical research, drug discovery, and vaccine development to effectively combat the emerging novel and re-emerging genetic variants of microbes.
format	article
author	Venkataramana Kandi Tarun Kumar Suvvari Sabitha Vadakedath Vikram Godishala
author_facet	Venkataramana Kandi Tarun Kumar Suvvari Sabitha Vadakedath Vikram Godishala
author_sort	Venkataramana Kandi
title	Microbes, Clinical trials, Drug Discovery, and Vaccine Development: The Current Perspectives
title_short	Microbes, Clinical trials, Drug Discovery, and Vaccine Development: The Current Perspectives
title_full	Microbes, Clinical trials, Drug Discovery, and Vaccine Development: The Current Perspectives
title_fullStr	Microbes, Clinical trials, Drug Discovery, and Vaccine Development: The Current Perspectives
title_full_unstemmed	Microbes, Clinical trials, Drug Discovery, and Vaccine Development: The Current Perspectives
title_sort	microbes, clinical trials, drug discovery, and vaccine development: the current perspectives
publisher	Institute for Researches and Community Services Universitas Muhammadiyah Palangkaraya
publishDate	2021
url	https://doaj.org/article/3bf383f07f1444fe90c3cc054d9d84e5
work_keys_str_mv	AT venkataramanakandi microbesclinicaltrialsdrugdiscoveryandvaccinedevelopmentthecurrentperspectives AT tarunkumarsuvvari microbesclinicaltrialsdrugdiscoveryandvaccinedevelopmentthecurrentperspectives AT sabithavadakedath microbesclinicaltrialsdrugdiscoveryandvaccinedevelopmentthecurrentperspectives AT vikramgodishala microbesclinicaltrialsdrugdiscoveryandvaccinedevelopmentthecurrentperspectives
_version_	1718405770888871936

Microbes, Clinical trials, Drug Discovery, and Vaccine Development: The Current Perspectives

Ejemplares similares